Adenovirus-mediated gene therapy of liver diseases

Yaron Ilan, Hidetsugu Saito, Narsing R. Thummala, Namita Roy Chowdhury

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Recombinant adenoviruses can infect nondividing cells with high efficiency and are rapidly concentrated in the liver after systemic administration, making them attractive for use in liver-directed gene therapy. However, there are two hurdles to clinical application of these vectors. First, adenoviruses are episomal and have limited life spans within the cell. Second, host antiviral immune responses reduce the duration of vector persistence and preclude long-term transgene expression by repeated injection of the vector. Several strategies have been designed for abrogation of the specific antiadenoviral immune responses by modification of the host immune system or alteration of the vector. These strategies and the use of adenoviral vectors for the treatment of hereditary, infectious, and malignant diseases of the liver are discussed in this review.

Original languageEnglish
Pages (from-to)49-59
Number of pages11
JournalSeminars in Liver Disease
Volume19
Issue number1
Publication statusPublished - 1999

Fingerprint

Adenoviridae
Genetic Therapy
Liver Diseases
Liver
Transgenes
Antiviral Agents
Communicable Diseases
Immune System
Injections
Therapeutics

Keywords

  • Adenoviral vectors
  • Gene therapy
  • Hepatic malignancies
  • Hereditary diseases
  • Infectious diseases

ASJC Scopus subject areas

  • Hepatology

Cite this

Ilan, Y., Saito, H., Thummala, N. R., & Roy Chowdhury, N. (1999). Adenovirus-mediated gene therapy of liver diseases. Seminars in Liver Disease, 19(1), 49-59.

Adenovirus-mediated gene therapy of liver diseases. / Ilan, Yaron; Saito, Hidetsugu; Thummala, Narsing R.; Roy Chowdhury, Namita.

In: Seminars in Liver Disease, Vol. 19, No. 1, 1999, p. 49-59.

Research output: Contribution to journalArticle

Ilan, Y, Saito, H, Thummala, NR & Roy Chowdhury, N 1999, 'Adenovirus-mediated gene therapy of liver diseases', Seminars in Liver Disease, vol. 19, no. 1, pp. 49-59.
Ilan Y, Saito H, Thummala NR, Roy Chowdhury N. Adenovirus-mediated gene therapy of liver diseases. Seminars in Liver Disease. 1999;19(1):49-59.
Ilan, Yaron ; Saito, Hidetsugu ; Thummala, Narsing R. ; Roy Chowdhury, Namita. / Adenovirus-mediated gene therapy of liver diseases. In: Seminars in Liver Disease. 1999 ; Vol. 19, No. 1. pp. 49-59.
@article{06951323532b41c698b1bb66446494da,
title = "Adenovirus-mediated gene therapy of liver diseases",
abstract = "Recombinant adenoviruses can infect nondividing cells with high efficiency and are rapidly concentrated in the liver after systemic administration, making them attractive for use in liver-directed gene therapy. However, there are two hurdles to clinical application of these vectors. First, adenoviruses are episomal and have limited life spans within the cell. Second, host antiviral immune responses reduce the duration of vector persistence and preclude long-term transgene expression by repeated injection of the vector. Several strategies have been designed for abrogation of the specific antiadenoviral immune responses by modification of the host immune system or alteration of the vector. These strategies and the use of adenoviral vectors for the treatment of hereditary, infectious, and malignant diseases of the liver are discussed in this review.",
keywords = "Adenoviral vectors, Gene therapy, Hepatic malignancies, Hereditary diseases, Infectious diseases",
author = "Yaron Ilan and Hidetsugu Saito and Thummala, {Narsing R.} and {Roy Chowdhury}, Namita",
year = "1999",
language = "English",
volume = "19",
pages = "49--59",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "1",

}

TY - JOUR

T1 - Adenovirus-mediated gene therapy of liver diseases

AU - Ilan, Yaron

AU - Saito, Hidetsugu

AU - Thummala, Narsing R.

AU - Roy Chowdhury, Namita

PY - 1999

Y1 - 1999

N2 - Recombinant adenoviruses can infect nondividing cells with high efficiency and are rapidly concentrated in the liver after systemic administration, making them attractive for use in liver-directed gene therapy. However, there are two hurdles to clinical application of these vectors. First, adenoviruses are episomal and have limited life spans within the cell. Second, host antiviral immune responses reduce the duration of vector persistence and preclude long-term transgene expression by repeated injection of the vector. Several strategies have been designed for abrogation of the specific antiadenoviral immune responses by modification of the host immune system or alteration of the vector. These strategies and the use of adenoviral vectors for the treatment of hereditary, infectious, and malignant diseases of the liver are discussed in this review.

AB - Recombinant adenoviruses can infect nondividing cells with high efficiency and are rapidly concentrated in the liver after systemic administration, making them attractive for use in liver-directed gene therapy. However, there are two hurdles to clinical application of these vectors. First, adenoviruses are episomal and have limited life spans within the cell. Second, host antiviral immune responses reduce the duration of vector persistence and preclude long-term transgene expression by repeated injection of the vector. Several strategies have been designed for abrogation of the specific antiadenoviral immune responses by modification of the host immune system or alteration of the vector. These strategies and the use of adenoviral vectors for the treatment of hereditary, infectious, and malignant diseases of the liver are discussed in this review.

KW - Adenoviral vectors

KW - Gene therapy

KW - Hepatic malignancies

KW - Hereditary diseases

KW - Infectious diseases

UR - http://www.scopus.com/inward/record.url?scp=0032948552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032948552&partnerID=8YFLogxK

M3 - Article

C2 - 10349683

AN - SCOPUS:0032948552

VL - 19

SP - 49

EP - 59

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - 1

ER -